Shuttle Pharmaceuticals Holdings, Inc. (SHPH) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Shuttle Pharmaceuticals is a discovery and development-stage biopharmaceutical company focused on developing novel therapies to sensitize cancer cells to radiation therapy and protect normal tissues. The company's lead candidate, Ropidoxuridine, has received FDA approval for a Phase II clinical trial in glioblastoma patients. The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,762,246) | $(3,159,468) |
| Net Loss Per Share (Basic & Diluted) | $(1.80) | $(1.81) |
| Cash and Cash Equivalents (End of Period) | $695,594 | $5,446,786 |
| Marketable Securities | $1,642,995 | $2,887,215 |
| Working Capital | $1,100,713 | $4,550,768 |
| Convertible Notes Payable (Net) | $826,235 (Current) | $731,088 (Current + Non-Current) |
| Operating Cash Flow | $(2,638,425) | $(2,984,039) |
Material Changes vs. Prior Period
- Liquidity Decline: Cash and cash equivalents decreased by approximately $1.9 million (87%) year-over-year, driven by operating losses and debt repayments. Working capital declined by 76% to $1.1 million.
- Operating Expenses: Total operating expenses decreased slightly by 5% to $2.9 million. Research and Development (R&D) expenses dropped 30% to $1.2 million as the company completed drug product manufacturing and awaited trial initiation. However, Legal and Professional fees increased 28% to $1.0 million due to public filing and financing requirements.
- Debt and Derivatives: The company settled $501,667 of convertible note principal in cash and issued 78,197 shares to settle accrued interest and principal. Interest expense decreased 30% to $0.9 million. The company recognized a $54,089 gain on the change in fair value of derivative liabilities, compared to a $1.7 million gain in the prior year.
- Stock Split: A 1-for-8 reverse stock split was effectuated on August 13, 2024, to meet Nasdaq listing requirements. All share data in this report has been retroactively adjusted.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months. Existing cash and marketable securities are insufficient to fund operations and clinical trials through that period.
- Financing Needs: The company is actively pursuing additional equity or debt financing. A planned $4.5 million rights offering has not yet been consummated as of the filing date. In August 2024, the company engaged an underwriter for a potential offering of up to $10.0 million.
- Debt Default and Waiver: In July 2024, the company notified its convertible note investor that an expected restatement of prior financials constituted an event of default. On August 6, 2024, the company paid $600,000 to the investor as collateral and received a waiver of the default.
- Clinical Progress: The Phase II trial for Ropidoxuridine in glioblastoma is on track. The company entered a work order with a CRO (Theradex Systems) in August 2024 to oversee the study, with a fee of approximately $2.3 million over 53 months.
- Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of June 30, 2024, citing material weaknesses in accounting policies, segregation of duties, and financial reporting oversight. A new CFO was hired in Q2 2024 to assist with remediation.
Investor Verification Checklist
- Capital Runway: Verify the status of the $4.5 million rights offering and the $10.0 million financing commitment to confirm if the company can fund operations beyond the current quarter.
- Debt Covenants: Monitor the terms of the Alto Convertible Note, specifically the $600,000 collateral payment and the conditions of the default waiver received in August 2024.
- Restatement Impact: Review the details of the expected restatement of 2022 and 2023 financial statements that triggered the debt default notice.
- Internal Controls: Assess the progress of remediation efforts regarding the identified material weaknesses in internal controls over financial reporting.
- Clinical Trial Costs: Confirm the funding source for the $2.3 million CRO contract signed in August 2024 for the Phase II trial.